If you own valuable IP, you’ve probably wrestled with this question:
How do I move this forward without betting the entire company—or my personal finances—on one outcome?
That tension sits at the heart of many licensing decisions. You see the opportunity. You believe in the IP. However, the costs, risks, and uncertainties of commercialization can feel overwhelming.
A recent real-world licensing deal in biotech shows a powerful way companies solve this problem—and it’s a strategy you can apply far beyond pharma.
The Real-World Example: Rani Therapeutics and Chugai
Rani Therapeutics entered into a significant licensing agreement with Chugai Pharmaceutical, a global pharmaceutical company and subsidiary of Roche.
The deal—valued at up to $1.09 billion in upfront payments, development milestones, and royalties—focused on Rani’s proprietary oral biologics delivery technology.
It’s a significant number. But the real lesson isn’t the dollar amount.
It’s how Rani used licensing to reduce risk, preserve ownership, and keep long-term upside.
The Problem You May Be Facing Right Now
If you’re honest, at least one of these probably sounds familiar:
- Your IP has strong potential, but development costs are high
- Commercialization requires expertise you don’t have in-house
- Raising more capital feels dilutive or risky
- Going it alone would stretch your team too thin
Rani faced a similar challenge—just at a different scale.
Instead of trying to fund and execute everything internally, they made a strategic decision: share the risk with a partner who already knows how to execute.
What Rani Did (and Why It Matters to You)
Rather than selling the company or giving up control of the technology, Rani:
- Licensed specific rights to a qualified partner
- Structured payments around progress, not promises
- Retained long-term participation through royalties
- Preserved flexibility for other markets and future deals
This is a textbook example of risk-sharing through licensing.
You don’t need to be a biotech company to use this approach. The same strategy applies to:
- Medical devices and diagnostics
- Software and platforms
- Industrial process technologies
- Advanced materials and manufacturing IP
Any time commercialization is expensive, slow, or uncertain, licensing can shift the risk off your balance sheet.
The Strategic Insight You Can Use
Here’s the key takeaway:
Licensing isn’t about giving up value. It’s about choosing where you carry risk—and where you don’t.
When appropriately structured, licensing allows you to:
- Move forward without overextending yourself
- Let experienced partners handle execution
- Get paid as progress happens
- Keep long-term upside instead of exiting too early
This is especially powerful if your IP is strong, but your resources are limited—or better spent elsewhere.
Why This Approach Often Works Better Than “Going It Alone”
Many IP owners assume the only way to capture full value is to build everything themselves.
In reality, that approach often leads to:
- Burnout
- Delays
- Capital constraints
- Missed market windows
Licensing offers an alternative path—one where progress and protection coexist.
The smartest companies don’t ask, “How do we do everything?”
They ask, “Who is best positioned to do what?”
How Licensing Consulting Group Helps You Apply This Strategy
Seeing the strategy is one thing. Applying it to your IP is another.
Licensing Consulting Group (LCG) helps IP owners like you determine:
- Whether licensing is the right risk-management strategy
- Which markets and partners make sense
- How to structure deals that protect your interests
- How to engage partners through outbound licensing campaigns
- How to move conversations toward real agreements
The goal isn’t just to license IP—it’s to use licensing to support your business and personal objectives.
Ask Yourself This
If commercialization feels risky, expensive, or overwhelming, ask:
- Where could licensing reduce my exposure?
- Who already has the infrastructure I lack?
- What would progress look like if risk were shared?
These are the same questions companies like Rani asked—before choosing licensing as their path forward.
Take the Next Step
If you’re exploring how to move your IP forward without taking on unnecessary risk, a short strategy conversation can help clarify your options.
👉 Schedule a Licensing Strategy Call with Licensing Consulting Group
We’ll discuss your IP, your market, and whether a risk-sharing licensing approach makes sense for you.
Stay Informed on Real-World Licensing Strategies
Licensing deals like this one aren’t isolated events—they’re signals.
📩 Subscribe to the Licensing Consulting Group Newsletter to receive:
- Real-world licensing deal breakdowns
- Practical strategies IP owners can apply
- Insights from active outbound licensing campaigns
This article is part of our ongoing series breaking down real licensing deals—one strategy at a time. Each article focuses on what you can learn and apply, regardless of industry or company size.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.